IM HealthScience releases two clinicals supporting efficacy of IBgard and FDgard

LAS VEGAS – IM HealthScience earlier this week announced results from a pair of clinical trials supporting the use of IBgard and FDgard, respectively.



First, IM HealthScience released the complete and final results of IBSACT (Irritable Bowel Syndrome Adherence and Compliance Trial), a real-world observational study of 630 patients who took IBgard, a medical food for the dietary management of Irritable Bowel Syndrome. Data from IBSACT determined that there was a high level of patient satisfaction with the product even among those patients taking several capsules on a daily basis - as many as 70% of the patients felt relief of abdominal pain, discomfort and/or bloating within 2 hours while 94% of patients reported relief within 24 hours after taking IBgard.



"Irritable bowel syndrome is an important health issue which drastically affects quality of life," stated Darren Brenner, director of the Gastrointestinal Motility Program, Feinberg School of Medicine at Northwestern University in Chicago. "People with IBS need to be proactive about their condition and talk to their doctor about helping them manage their IBS symptoms. In my experience, IBgard fills an unmet need among IBS patients for rapid and well-tolerated relief of IBS symptoms.”



IM HealthScience also released interim results of FDACT (Functional Dyspepsia Adherence and Compliance Trial), a real-world observational study of 205 patients who took FDgard, a new, non-prescription medical food specially formulated for the dietary management of functional dyspepsia. FD has been characterized as persistent or recurring indigestion with no known organic cause. Currently, there are few options for doctors and their patients to manage FD.   

Interim data from FDACT found that more than 92% of patients reported major or moderate improvement in their symptoms of FD (persistent or recurring indigestion) while 87% of patients indicated that their relief from indigestion was attained in two hours or less after taking FDgard.



“Functional dyspepsia can have a significant impact on one’s quality of life,” commented  Matthew Soff, a practicing gastroenterologist affiliated with Westside Regional Medical Center in Plantation, Fla., and North Shore Medical Center in Ft. Lauderdale, Fla.. “There are newly published criteria to help physicians diagnose FD, but up until now, treatment options have been limited, with few effective agents," he said. "In my experience, FDgard has been a great addition for fast relief of frustrating FD symptoms. This natural product effectively controls the upper abdominal pain, the feeling of early fullness with a meal, and the nausea, belching and bloating that are so bothersome to FD patients."